Claims
- 1. A method of inhibiting formation of glycation endproducts or protein crosslinking in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1 [(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxyl isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 2. A method of slowing deleterious effects of aging in an organism wherein said effects are formation of glycation endproducts or protein crosslinking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxy]isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, a-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 3. A method of slowing progress in a patient of complications resulting from diabetes wherein said complications result from formation of glycation endproducts or protein crosslinking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108:1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109:1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxy]isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 4. A method of slowing progress in a patient of rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, or atherosclerosis, wherein said method comprises administering an effective amount of a compound or a pharmaccutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1 [(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid. LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxy]isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 5. A method of preventing spoilage of proteins in foodstuffs wherein said method comprises mixing an effective amount of a compound or a pharmaceutically acceptable salt of said compound with said foodstuffs, wherein said effective amount inhibits formation of glycation endproducts or protein crosslinking, wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl]-2-carboxylic acid, LR105: 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxy]isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 6. A compound or a pharmaceutically acceptable salt of said compound wherein said compound is selected from the group consisting of:
LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido) phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis [(methyleneoxyethyleneamino) phenoxy] isobutyric acid, LR113: L-8-quinolinolyl (acetylhistidine), LR114: 4-[(3,5=dichlorophenyureido) phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.
- 7. A pharmaceutical composition comprising an effective amount of i) a compound or a pharmaceutically acceptable salt of said compound and ii) a pharmaceutical carrier, wherein said compound is a compound of claim 6.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of application Ser. No. 09/800,976, filed Mar. 8, 2001, which is a continuation-in-part of application Ser. No. 09/543,703, filed Apr. 5, 2000, now U.S. Pat. No. 6,337,350, which is related to provisional application Serial No. 60/127,835, filed Apr. 5, 1999, which are all incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60127835 |
Apr 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09800976 |
Mar 2001 |
US |
Child |
10358403 |
Feb 2003 |
US |
Parent |
09543703 |
Apr 2000 |
US |
Child |
09800976 |
Mar 2001 |
US |